One-Shot antibody shields kids from malaria in High-Risk kenya
NCT ID NCT05400655
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 20 times
Summary
This study tested a single injection of a lab-made antibody (L9LS) in healthy children aged 5 months to 10 years in western Kenya, where malaria is common. The goal was to see if it safely prevents Plasmodium falciparum infection. Results showed the antibody was well-tolerated and reduced the risk of malaria during the trial period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kenya Medical Research Institute (KEMRI) Center for Global Health Research (CGHR)
Kisumu, Kenya
Conditions
Explore the condition pages connected to this study.